Clinicopathological characteristics of triple-negative invasive mammary carcinomas in African-American versus Caucasian women

Annals of Clinical and Laboratory Science

Volumn 40, Issue 4, 2010, Pages 315-323

  Tawfik, Ossama ^a   Davis, Keisha ^a   Kimler, Bruce F ^a   Davis, Marilyn K ^a   Hull, Stephanie ^a   Fan, Fang ^a   Khan, Qamar J ^a   O'Dea, Anne P ^a   Thomas, Patricia ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

Breast carcinoma grading; Immunohistochemical staining; MIB 1 (ki 67)

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; PROTEIN BCL 2; PROTEIN P21; PROTEIN P27; PROTEIN P53;

ADULT; AFRICAN AMERICAN; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER SURVIVAL; CAUCASIAN; ETHNICITY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RACE DIFFERENCE; TRIPLE NEGATIVE INVASIVE CARCINOMA; TUMOR VOLUME;

AFRICAN AMERICANS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 77958066683     PISSN: 00917370     EISSN: 15508080     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Reis-Filho JS, Simpson PT, Gale T, Lakhani SR.. The molecular genetics of breast cancer: The contribution of comparative genomic hybridization. Pathol Res Pract 2005;201:713-725. (Pubitemid 41671175)
2. Lacroix M, Toillon RA, Leclercq G. Stable 'portrait' of breast tumors during progression: Data from biology, pathology and genetics. Endocr Relat Cancer 2004;11: 497-522.
3. Simpson PT, Reis-Filho JS, Gale T, Lakhani SR. Molecular evolution of breast cancer. J Pathol 2005, 205:248-254.
4. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumors. Nature 2000;406:747-752.
5. Mattie MD, Benz CC, Bowers J, Sensinger K, Wong L, Scott GK, Fedele V, Ginzinger D, Getts R, Haqq C. Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer 2006; 5:24.
6. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO. High throughput protein expression analysis using tissue microarray technology of a large well-characterized series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 2005;116:340-350.
7. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P, Børresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. PNAS USA 2001;98;10869-10874.
8. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 2006;37:1217-1226.
9. Tischkowitz M, Brunet JS, Bégin LR, Huntsman DG, Cheang MC, Akslen LA, Nielsen TO, Foulkes WD. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 2007;7:134.
10. Rodríguez-Pinilla SM, Sarrió D, Honrado E, Hardisson D, Calero F, Benitez J, Palacios J. Prognostic significance of basal-like phenotype and fascin expression in nodenegative invasive breast carcinomas. Clin Cancer Res 2006;12:1533-1539.
11. Rakha EA, Putti TC, Abd El-Rehim DM, Paish C, Green AR, Powe DG, Lee AH, Robertson JF, Ellis IO. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 2006;208:495-506.
12. Rakha EA, Reis-Filho JS, Ellis IO. Basal-like breast cancer: a critical review. J Clin Oncol 2008;26:2568-2581.
13. Fulford LG, Easton DF, Reis-Filho JS, Sofronis A, Gillett CE, Lakhani SR, Hanby A. Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast. Histopathology 2006;49:22-34.
14. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006;19:264-271.
15. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO. Prognostic markers in triple-negative breast cancer. Cancer 2007;109:25-32.
16. Umemura S, Takekoshi S, Suzuki Y, Saitoh Y, Tokuda Y, Osamura RY. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression. Oncol Rep 2005;14:337-343.
17. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-2502.
18. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen receptor (ER)-negative invasive breast cancer, the so-called triple-negative phenotype: A population-based study from the Carolina cancer registry. Cancer 2007;109:1721-1728.
19. Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, Schwartz GF, Park PK, Rosenberg AL, Brill K, Mitchell EP. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 2007;110:876-884.
20. Stark A, Kapke A, Schultz D, Brown R, Linden M, Raju U. Advanced stages and poorly differentiated grade are associated with an increased risk of HER2/neu positive breast cancer only in white women: findings from a prospective cohort study of African-American and white-American women. Breast Cancer Res Treat 2008; 107:405-414. (Pubitemid 351172112)
21. Henson DE, Chu KC, Levine PH. Histologic grade, stage, and survival in breast cancer: comparison of African American and Caucasian women. Cancer 2003; 98:908-917.
22. Amend K, Hicks D, Ambrosone CB. Breast cancer in African-American women: differences in tumor biology from European-American women. Cancer Res 2006;66: 8327-8330.
23. Ries LA, Melbert DL, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2004. National Cancer Institute, Bethesda, MD, 2006.
24. Polite BN, Cirrincione C, Fleming GF, Berry DA, Seidman A, Muss H, Norton L, Shapiro C, Bakri K, Marcom K, Lake D, Schwartz JH, Hudis C, Winer EP. Racial differences in clinical outcomes from metastatic breast cancer: a pooled analysis of CALGB 9342 and 9840 Cancer & Leukemia Group B. J Clin Oncol 2008; 26:2659-2665.
25. Lund MJ, Trivers KF, Porter PL, Coates RJ, Leyland- Jones B, Brawley OW, Flagg EW, O'Regan RM, Gabram SG, Eley JW. Race and triple negative threats to breast cancer survival: A population-based study in Atlanta, GA. Breast Cancer Res Treat 2009;113:357-370.
26. Reis-Filho JS, Milanezi F, Steele D, Savage K, Simpson PT, Nesland JM, Pereira EM, Lakhani SR, Schmitt FC. Metaplastic breast carcinomas are basal-like tumours. Histopathology 2006;49:10-21.
27. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow up. Histopathology 1991;19:403-410.
28. Vincent-Salomon A, Gruel N, Lucchesi C, MacGrogan G, Dendale R, Sigal-Zafrani B, Longy M, Raynal V, Pierron G, de Mascarel I, Taris C, Stoppa-Lyonnet D, Pierga JY, Salmon R, Sastre-Garau X, Fourquet A, Delattre O, de Cremoux P, Aurias A. Identification of typical medullary breast carcinoma as a genomic subgroup of basal-like carcinomas, a heterogeneous new molecular entity. Breast Cancer Res 2007;9:R24.
29. Jacquemier J, Padovani L, Rabayrol L, Lakhani SR, Penault-Llorca F, Denoux Y, Fiche M, Figueiro P, Maisongrosse V, Ledoussal V, Martinez Penuela J, Udvarhely N, El Makdissi G, Ginestier C, Geneix J, Charafe-Jauffret E, Xerri L, Eisinger F, Birnbaum D, Sobol H; European Working Group for Breast Screening Pathology; Breast Cancer Linkage Consortium. Typical medullary breast carcinomas have a basal/myoepithelial phenotype. J Pathol 2005;207:260-268.